The powerful world of antisense oligonucleotides: From bench to bedside

Anais M. Quemener (1) , Laura Bachelot (1) , Anne Forestier (1) , Emmanuelle Donnou-Fournet (1) , David Gilot (1) , Marie-Dominique Galibert (1, 2)

1 IGDR - Institut de Génétique et Développement de Rennes
2 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]

Antisense oligonucleotides (ASOs) represent a new and highly promising class of drugs for personalized medicine. In the last decade, major chemical developments and improvements of the backbone structure of ASOs have transformed them into true approved and commercialized drugs. ASOs target both DNA and RNA, including pre-mRNA, mRNA, and ncRDA, based on sequence complementary. They are designed to be specific for each identified molecular and genetic alteration to restore a normal, physiological situation. Thus, the characterization of the underpinning mechanisms and alterations that sustain pathology is critical for accurate ASO-design. ASOs can be used to cure both rare and common diseases, such as orphan genetic alterations and cancer. Through pioneering examples, this review shows the versatility of the mechanisms of action that provide ASOs with the potential capacity to achieve custom treatment, revolutionizing personalized medicine. This article is categorized under RNA in Disease and Development > RNA in Disease RNA Interactions with Proteins and Other Molecules > Small Molecule-RNA Interactions

Mots clés: antisense oligonucleotide; ASO-therapy; cancer; genetic disoders; miRNA sponge

Domaines: Sciences du Vivant [q-bio]; Génétique; Cancer

Anais M. Quemener, Laura Bachelot, Anne Forestier, Emmanuelle Donnou-Fournet, David Gilot, et al.. The powerful world of antisense oligonucleotides: From bench to bedside. Wiley Interdisciplinary Reviews-RNA, 2020, 11 (5), pp.e1594. ⟨10.1002/wrna.1594⟩. ⟨hal-02565099⟩